Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTIC: Carvedilol for Trastuzumab-Induced Cardiotoxicity in Breast Cancer
NCT03879629Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Aug 2019
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of carvedilol in cardiomyopathy, sponsored by Mayo Clinic. Started Aug 2019; status: terminated.
02
Drugs
carvedilol
03
Conditions
cardiomyopathy
Beyond the preview
Go deeper on NCT03879629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03879629.